SCVC
Overview
SCVC is a UK venture capital firm that invests in early-stage deep tech spin-outs, focusing on advanced technologies from biotech to quantum tech. They partner with technical founders aligned with their mission of improving the health of people and the planet. SCVC is the official VC arm of Science Creates.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| EpimAb Biotherapeutics | Jun 2019 | Series B | Co-investor |
| Inmagene | Nov 2020 | Series B | Co-investor |
| Houdini Bio | Jun 2026 | Pre Seed | Lead |
| Scarlet Therapeutics | May 2026 | Seed | Co-investor |
| Portal Biotechnologies | Jun 2025 | Series A | Co-investor |
For institutional investors. Book with your work email.
Key People
Harry Destecroix
Co Founder & Managing Partner
Catherine Fletcher
General Partner
John Williams
General Partner
Laura Davies
Principal
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is SCVC based?
SCVC is headquartered in Bristol, England, United Kingdom.
When was SCVC founded?
SCVC was founded in 2020.
How many portfolio companies does SCVC have?
SCVC has 8 portfolio companies in Caplight's dataset.
What are some companies in SCVC's portfolio?
Portfolio companies visible on Caplight include EpimAb Biotherapeutics, Inmagene, Houdini Bio, Scarlet Therapeutics, Portal Biotechnologies.
What was SCVC's most recent investment shown here?
SCVC's most recent investment in this portfolio sample was in Houdini Bio in 2026.
What sectors does SCVC focus on?
SCVC focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Mobility, Transportation & Logistics, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does SCVC focus on?
SCVC typically invests at the Early stage.
What is SCVC's AUM?
SCVC's assets under management are estimated between $50.0M and $100.0M.